Product
Verorab
Aliases
Purified inactivated rabies vaccine - Verorab®
4 clinical trials
3 indications
Indication
RabiesIndication
MalariaIndication
MeaslesClinical trial
Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With Verorab® and Imovax® Rabies, in a Pre-exposure Regimen in Both Pediatric and Adult Populations and a Single Booster Dose of Purified Vero Rabies Vaccine - Serum Free Administered at 1 Year Post-3-dose Primary Series, and Between 2 up to 3 Years Post-One Week 2-Dose Primary Series in a Subset of Adults in ThailandStatus: Active (not recruiting), Estimated PCD: 2020-03-25
Clinical trial
Phase 1, Dose-Escalating, Double-Blind, Randomized, Comparator-Controlled Trial of the Safety, Tolerability, and Immunogenicity of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M™ Against Plasmodium Falciparum in Adults in MaliStatus: Completed, Estimated PCD: 2023-02-17
Clinical trial
A Randomised, Controlled, Double-blind, Parallel Group, Single Center Phase Ib Trial to Assess Safety, Reactogenicity and Immunogenicity of a Candidate Dual-stage Malaria Vaccine, SumayaVac-1 (MSP-1 With GLA-SE as Adjuvant) in Healthy Malaria Exposed Adults of African Origin Aged 18-45 YearsStatus: Completed, Estimated PCD: 2024-04-02
Clinical trial
Investigation of Immune Amnesia Following Measles Infection in Select African RegionsStatus: Recruiting, Estimated PCD: 2025-06-01